Zeltiq, Gentherm Have Room to Run Says William Blair Fund Manager

Zeltiq's non-invasive fat removal system has the potential to replicate the success seen by Botox, said Michael Balkin, portfolio manager for the William Blair Small Cap Growth Fund. He added that the company's shares have room to run despite appreciating over 20% this year. Balkin said he is also bullish on ExamWorks, saying that insurance companies would prefer to work with a single, large-scale medical fraud examiner than smaller, local ones. Finally, Balkin said he is positive on Gentherm's stock despite its phenomenal run because it is expanding its heating and cooling technology beyond automobile parts.
View Comments (0)